Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H18O9 |
Molecular Weight | 390.3408 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C2=C(OCO2)C(OC)=C1)C3=C(CO)C=C(OC)C4=C3OCO4
InChI
InChIKey=KXMTXZACPVCDMH-UHFFFAOYSA-N
InChI=1S/C19H18O9/c1-22-11-4-9(6-20)13(17-15(11)25-7-27-17)14-10(19(21)24-3)5-12(23-2)16-18(14)28-8-26-16/h4-5,20H,6-8H2,1-3H3
Bicyclol, also known as SY 801, is a hepatoprotective agent. Bicyclol upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice. Bicyclol promotes toll-like 2 receptor recruiting inosine 5'-monophosphate dehydrogenase II to exert its anti-inflammatory effect. Phase Ⅰ~Ⅳ clinical trials and extensive application after market launch prove that, Bicyclol is suitable for the treatment of chronic viral and non-viral liver disease with elevated serum aminotransferase abnormalities, and is excellent in safety. This drug is recommended for liver protection and anti-inflammatory medication by Chinese Medical Association in Guidelines for Management of Alcoholic Fatty Liver Disease, Guidelines for Management of Non-alcoholic Fatty Liver Disease, The Guideline of Prevention and Treatment for Chronic Hepatitis B, Expert Consensus On Hepatic Inflammation and Its Prevention and other professional guidelines and consensus.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5976 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20139905 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Bicyclol Approved UseBicyclol is recommended for liver protection and anti-inflammatory medication by Chinese Medical Association in Guidelines for Management of Alcoholic Fatty Liver Disease, Guidelines for Management of Non-alcoholic Fatty Liver Disease, The Guideline of Prevention and Treatment for Chronic Hepatitis B, Expert Consensus On Hepatic Inflammation and Its Prevention and other professional guidelines and consensus. |
|||
Primary | Bicyclol Approved UseBicyclol is recommended for liver protection and anti-inflammatory medication by Chinese Medical Association in Guidelines for Management of Alcoholic Fatty Liver Disease, Guidelines for Management of Non-alcoholic Fatty Liver Disease, The Guideline of Prevention and Treatment for Chronic Hepatitis B, Expert Consensus On Hepatic Inflammation and Its Prevention and other professional guidelines and consensus. |
|||
Primary | Bicyclol Approved UseHepatitis C treatment |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19149648
Patients received bicyclol 25mg thrice daily for six months, then stopped treatment and followed up for 3 months. Oral administration of bicyclol normalized the elevated serum transaminases (ALT, AST) by approximately 50% in chronic viral hepatitis B and C, and also showed certain level of inhibiting HBV and HCV replication.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20139905
Bicyclol 50 umol/L induced HSP27 expression in HepG2 cells in a time-dependent manner.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
118159-48-1
Created by
admin on Sat Dec 16 04:02:17 GMT 2023 , Edited by admin on Sat Dec 16 04:02:17 GMT 2023
|
PRIMARY | |||
|
100000124474
Created by
admin on Sat Dec 16 04:02:17 GMT 2023 , Edited by admin on Sat Dec 16 04:02:17 GMT 2023
|
PRIMARY | |||
|
9821754
Created by
admin on Sat Dec 16 04:02:17 GMT 2023 , Edited by admin on Sat Dec 16 04:02:17 GMT 2023
|
PRIMARY | |||
|
DTXSID30152026
Created by
admin on Sat Dec 16 04:02:17 GMT 2023 , Edited by admin on Sat Dec 16 04:02:17 GMT 2023
|
PRIMARY | |||
|
9734122TH2
Created by
admin on Sat Dec 16 04:02:17 GMT 2023 , Edited by admin on Sat Dec 16 04:02:17 GMT 2023
|
PRIMARY | |||
|
SUB32557
Created by
admin on Sat Dec 16 04:02:17 GMT 2023 , Edited by admin on Sat Dec 16 04:02:17 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD